Targeting Eosinophilic Esophagitis with Modern Biologic Agents

Eosinophilic esophagitis is a chronic, immune-mediated condition of the esophagus that has emerged from relative obscurity over the past two decades to become a major focus of gastroenterology and allergy research across Australia and internationally. Characterised by dense eosinophilic infiltration of the esophageal mucosa, it produces dysphagia, food impaction, and chest pain that significantly impair quality of life.

For many years, management relied on proton pump inhibitors, topical corticosteroids such as swallowed fluticasone or budesonide, and elimination diets. While these approaches help selected patients, a substantial proportion continue to experience symptoms or require repeated endoscopic dilatation. This therapeutic gap has driven strong interest in biologic therapies that target the underlying type 2 inflammatory cascade, offering a more precise and durable disease-modifying strategy.

The Type 2 Inflammatory Signature in EoE

At the heart of eosinophilic esophagitis lies a dysregulated Th2 immune response, often triggered by food allergens and aeroallergens. Interleukin-5 drives eosinophil recruitment and survival, interleukin-13 promotes epithelial barrier dysfunction and remodeling, and IgE contributes to mast cell activation. Australian patients frequently present with comorbid atopic conditions, including asthma, allergic rhinitis, and atopic dermatitis, which reinforces the systemic nature of the disease and helps clinicians identify candidates for biologic intervention.

Because the condition tends to cluster in families and is more common in males, allergy clinics in Sydney and Melbourne have developed structured referral pathways for endoscopic biopsies after a trial of empiric elimination diets. These local protocols align with international consensus and aim to identify patients whose disease may respond to targeted immunomodulation rather than indefinite dietary restriction.

Dupilumab as the Leading Biologic Option

Dupilumab, a monoclonal antibody that blocks the shared receptor subunit for IL-4 and IL-13, has transformed the treatment landscape for eosinophilic esophagitis. Pivotal trials demonstrated significant reductions in esophageal eosinophil counts, improvements in endoscopic severity scores, and meaningful relief of dysphagia in both adolescent and adult participants. In Australia, the Therapeutic Goods Administration has registered dupilumab for EoE, and specialists are accumulating real-world experience across tertiary centres in Brisbane, Perth, and Adelaide.

Practical considerations include subcutaneous administration every one or two weeks, the need for ongoing therapy to maintain remission, and attention to injection-site reactions. Importantly, optimising preoperative nutrition before any esophageal procedure remains a parallel concern, particularly for patients with longstanding strictures who may require dilatation or surgical intervention.

Anti-IL-5 and Anti-IgE Approaches

Mepolizumab and reslizumab neutralise IL-5, the cytokine most directly responsible for eosinophil proliferation. Clinical studies have shown reductions in tissue eosinophilia, though symptom responses have been more modest than with IL-13 blockade, suggesting that eosinophil depletion alone may be insufficient to reverse the fibrotic and remodeling components of established disease. These agents are currently accessible in Australia for other indications such as severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.

Omalizumab, which targets IgE, has produced mixed results in EoE trials. While it may benefit patients with prominent atopic features, its overall efficacy in reducing esophageal eosinophils has been inconsistent. Use within Australia is therefore considered on a case-by-case basis, often through allergy specialists with access to shared decision-making frameworks.

Emerging Biologics and Combination Strategies

Several newer agents are advancing through clinical development. Mepolizumab is being evaluated at higher doses specifically for EoE, while investigational therapies targeting thymic stromal lymphopoietin, siglec-8, and IL-33 are entering phase 2 and 3 studies. Combination strategies that pair biologics with dietary elimination or topical steroids are also under investigation, aiming to achieve deeper remission with lower cumulative drug exposure.

For Australian clinicians, participation in international trials coordinated through the International Society for Diseases of the Esophagus offers an opportunity to contribute to this evolving evidence base. Rural and remote patients, however, still face barriers to enrolment due to travel requirements and limited access to specialty centres, highlighting the need for telehealth-supported models of care.

Comparing the Leading Biologic Agents

The following table summarises key features of the most studied monoclonal antibodies in eosinophilic esophagitis, including their mechanisms and current status within Australian therapeutic frameworks.

Local Access and Practice Considerations in Australia

Affordability and equitable access remain central concerns for Australian patients with eosinophilic esophagitis. The Pharmaceutical Benefits Scheme determines which biologics are subsidised, and a PBS listing for dupilumab in EoE would dramatically alter the treatment landscape for adults outside of private coverage. Until such listings are finalised, out-of-pocket costs can be considerable, prompting clinicians to advocate for expanded indications through professional societies and patient support groups.

Allied health involvement is equally important. Dietitians help guide empirical elimination protocols, speech pathologists assist with dysphagia rehabilitation, and endoscopists monitor histologic response. Multidisciplinary clinics in major teaching hospitals offer the most coordinated care, while outreach programs and telehealth consultations help bridge gaps for patients in regional Western Australia, Tasmania, and the Northern Territory.

Integrating biologic therapy into routine care for eosinophilic esophagitis requires careful patient selection, realistic discussion of expected outcomes, and coordination between gastroenterologists, allergists, and dietitians. Australian practitioners should remain alert to evolving Pharmaceutical Benefits Scheme listings, which substantially influence affordability and equitable access. As the evidence base matures, biologics are poised to complement rather than replace established dietary and endoscopic interventions, offering a more personalised path to durable remission for patients whose lives are shaped by this once-overlooked disease.